
ENESTnd data indicate trend for longer overall survival and event-free survival in newly diagnosed Ph+ CML patients on Tasigna versus Glivec[1] Data demonstrated higher rates of early and deeper molecular response in newly diagnosed patients, including MR4.5, and a reduced … Read the full press release